A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
grant eligible researchers access to eligible products at 
a discounted price for qualified research, and for other 
purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Discounted Drugs for 
4
Clinical Trials Act’’. 
5
00:14 Apr 09, 2022
H7472
2 
•HR 7472 IH
SEC. 2. DISCOUNTED SALES OF ELIGIBLE PRODUCTS FOR 
1
QUALIFIED RESEARCH PURPOSES. 
2
(a) IN GENERAL.—Chapter V of the Federal Food, 
3
Drug, and Cosmetic Act (21 U.S.C. 351 et seq.) is amend-
4
ed by inserting after section 505–2 of such Act (21 U.S.C. 
5
355–1) the following new section: 
6
‘‘SEC. 505–3. DISCOUNTED SALES OF ELIGIBLE PRODUCTS 
7
FOR QUALIFIED RESEARCH PURPOSES. 
8
‘‘(a) APPLICATION BY RESEARCHER.—To obtain an 
9
eligible product for qualified research at the discounted 
10
price, an individual or entity shall submit to the Secretary 
11
an application certifying and demonstrating that— 
12
‘‘(1) the individual or entity is an eligible re-
13
searcher; 
14
‘‘(2) the product being sought is an eligible 
15
product; 
16
‘‘(3) the researcher seeks to use the eligible 
17
product for qualified research; and 
18
‘‘(4) the amount of the eligible product sought 
19
is reasonable for completing the qualified research. 
20
‘‘(b) DUTIES OF SECRETARY.—The Secretary shall— 
21
‘‘(1) review each application submitted under 
22
paragraph (1) in a timely manner; 
23
‘‘(2) provide to the applicant, within a reason-
24
able time of such submission— 
25
00:14 Apr 09, 2022
H7472
3 
•HR 7472 IH
‘‘(A) a written order specifying the suffi-
1
cient quantity of the eligible product approved 
2
to be purchased by the eligible researcher at the 
3
discounted price; or 
4
‘‘(B) a written denial of the application; 
5
‘‘(3) require manufacturers and license holders 
6
to report to the Secretary any additional information 
7
determined by the Secretary to be necessary to carry 
8
out this section; and 
9
‘‘(4) annually publish information on the num-
10
ber and types of applications granted and denied 
11
under this section. 
12
‘‘(c) ACQUISITION OF DISCOUNTED DRUG.—Upon 
13
receipt from an eligible researcher of an order obtained 
14
under subsection (b)(2)(A) for the acquisition of an eligi-
15
ble product for qualified research, the manufacturer or li-
16
cense holder of the eligible product shall sell to the eligible 
17
researcher the quantity specified in the order at the dis-
18
counted price. 
19
‘‘(d) CIVIL ACTION FOR FAILURE TO PROVIDE SUF-
20
FICIENT QUANTITY OF AN ELIGIBLE PRODUCT.— 
21
‘‘(1) IN GENERAL.—An eligible researcher may 
22
bring a civil action against the manufacturer or li-
23
cense holder of an eligible product seeking relief 
24
under this subsection in an appropriate district 
25
00:14 Apr 09, 2022
H7472
4 
•HR 7472 IH
court of the United States alleging that the manu-
1
facturer or license holder has declined to provide the 
2
quantity of the eligible product specified in a written 
3
order from the Secretary to the eligible researcher 
4
for the discounted price. 
5
‘‘(2) ELEMENTS.—To prevail in a civil action 
6
brought under paragraph (1), an eligible researcher 
7
shall prove, by a preponderance of the evidence, 
8
that— 
9
‘‘(A) the eligible researcher has— 
10
‘‘(i) obtained a written order for the 
11
specified quantity of the eligible product 
12
from the Secretary in accordance with sub-
13
section (b)(2)(A); and 
14
‘‘(ii) provided a copy of the order to 
15
the manufacturer or license holder; and 
16
‘‘(B) as of the date on which the civil ac-
17
tion is filed, the eligible researcher has not ob-
18
tained the specified quantity of the eligible 
19
product at the discounted price by 31 days 
20
after the date on which the manufacturer or li-
21
cense holder received the eligible researcher’s 
22
request for the eligible product, including a 
23
copy of the written order. 
24
00:14 Apr 09, 2022
H7472
5 
•HR 7472 IH
‘‘(3) AFFIRMATIVE DEFENSE.—In a civil action 
1
brought under paragraph (1), it shall be an affirma-
2
tive defense, on which the defendant has the burden 
3
of persuasion by a preponderance of the evidence— 
4
‘‘(A) that, on the date on which the eligible 
5
researcher requested to purchase the specified 
6
quantity of the eligible product from the manu-
7
facturer or license holder— 
8
‘‘(i) neither the manufacturer, license 
9
holder, nor any of their agents, whole-
10
salers, or distributors, was engaged in the 
11
manufacturing or commercial marketing of 
12
the eligible product; and 
13
‘‘(ii) neither the manufacturer, license 
14
holder, nor any of their agents, whole-
15
salers, or distributors, otherwise had access 
16
to inventory of the eligible product to sup-
17
ply the specified quantity to the eligible re-
18
searcher at the discounted price; 
19
‘‘(B) that— 
20
‘‘(i) the manufacturer or license hold-
21
er sells the eligible product through agents, 
22
distributors, or wholesalers; 
23
‘‘(ii) the manufacturer has placed no 
24
restrictions, explicit or implicit, on its 
25
00:14 Apr 09, 2022
H7472
6 
•HR 7472 IH
agents, distributors, or wholesalers on sell-
1
ing the eligible product to eligible research-
2
ers; and 
3
‘‘(iii) the eligible product can be pur-
4
chased by the eligible researcher in the 
5
specified quantity at the discounted price 
6
or a lower price from the agents, distribu-
7
tors, or wholesalers of the manufacturer or 
8
license holder; or 
9
‘‘(C) that the manufacturer or license hold-
10
er made an offer to sell the specified quantity 
11
of the eligible product to the eligible researcher 
12
for the discounted price and the eligible re-
13
searcher did not accept such offer by the date 
14
that is 14 days after the date on which the eli-
15
gible product researcher received such offer. 
16
‘‘(4) METHODS
FOR
TRANSMISSION
OF
RE-
17
QUESTS FOR ELIGIBLE PRODUCTS.—A written re-
18
quest for an eligible product, offer to sell an eligible 
19
product, or acceptance of such an offer between the 
20
eligible researcher and the manufacturer or license 
21
holder of the eligible product shall be made by— 
22
‘‘(A) certified or registered mail with re-
23
turn receipt requested; 
24
‘‘(B) personal delivery; or 
25
00:14 Apr 09, 2022
H7472
7 
•HR 7472 IH
‘‘(C) electronic means. 
1
‘‘(5) REMEDIES.—If an eligible researcher pre-
2
vails in a civil action brought under paragraph (1), 
3
the court shall— 
4
‘‘(A) order the manufacturer or license 
5
holder to provide to the eligible researcher with-
6
out delay the specified quantity of the eligible 
7
product at the discounted price; 
8
‘‘(B) award to the eligible researcher rea-
9
sonable attorney’s fees and costs of the civil ac-
10
tion; and 
11
‘‘(C) award to the eligible researcher a 
12
monetary amount sufficient to deter the manu-
13
facturer or license holder from failing to provide 
14
eligible researchers with a sufficient quantity of 
15
an eligible product at the discounted price, if 
16
the court finds, by a preponderance of the evi-
17
dence, that the manufacturer or license holder, 
18
without a legitimate business justification— 
19
‘‘(i) delayed providing the specified 
20
quantity to the eligible researcher; or 
21
‘‘(ii) failed to comply with a written 
22
order under subsection (b)(2)(A). 
23
‘‘(6) MAXIMUM MONETARY AMOUNT.—A mone-
24
tary amount awarded under paragraph (5) shall not 
25
00:14 Apr 09, 2022
H7472
8 
•HR 7472 IH
be greater than the revenue that the manufacturer 
1
or license holder earned on the eligible product be-
2
ginning on the date that is 31 days after the date 
3
on which the manufacturer or license holder received 
4
the request and ending on the date on which the eli-
5
gible researcher received the specified quantity of 
6
the eligible product. 
7
‘‘(7) AVOIDANCE OF DELAY.—The court may 
8
issue an order under paragraph (5)(A) before con-
9
ducting further proceedings that may be necessary 
10
to determine— 
11
‘‘(A) whether the eligible researcher is en-
12
titled to an award under subparagraph (B) or 
13
(C) of paragraph (5); or 
14
‘‘(B) the amount of any such award. 
15
‘‘(e) LIMITATION OF LIABILITY.—A manufacturer or 
16
license holder of an eligible product obtained by an eligible 
17
researcher pursuant to this section shall not be liable for 
18
any claim under Federal, State, or local law arising out 
19
of the failure of the eligible researcher to follow adequate 
20
safeguards to assure safe use of the eligible product, in-
21
cluding with respect to transportation, handling, use, or 
22
disposal. 
23
‘‘(f) RULE OF CONSTRUCTION.—This section shall 
24
not be construed to— 
25
00:14 Apr 09, 2022
H7472
9 
•HR 7472 IH
‘‘(1) undermine or abrogate any requirement 
1
imposed pursuant to a risk evaluation and mitiga-
2
tion strategy under section 505–1; or 
3
‘‘(2) interfere with the private right of action 
4
afforded under section 610 of division N of the Fur-
5
ther Consolidated Appropriations Act, 2020 (Public 
6
Law 116–94) (21 U.S.C. 355–2 note; commonly re-
7
ferred to as the ‘CREATES Act’). 
8
‘‘(g) DEFINITIONS.—In this section: 
9
‘‘(1) 
COMMISSIONER.—The 
term 
‘Commis-
10
sioner’ means the Commissioner of Food and Drugs. 
11
‘‘(2) COMBINATION PRODUCT.—The term ‘com-
12
bination product’ means a combination product de-
13
scribed in section 503(g). 
14
‘‘(3) DISCOUNTED
PRICE.—The term ‘dis-
15
counted price’ means the direct costs to the manu-
16
facturer or license holder of producing the eligible 
17
product. 
18
‘‘(4) ELIGIBLE PRODUCT.—The term ‘eligible 
19
product’ means— 
20
‘‘(A) any— 
21
‘‘(i) drug approved under section 
22
505(c) of this Act or biological product li-
23
censed under section 351(a) of the Public 
24
Health Service Act; 
25
00:14 Apr 09, 2022
H7472
10 
•HR 7472 IH
‘‘(ii) combination product including 
1
such a drug or biological product; or 
2
‘‘(iii) product, including any device, 
3
that is marketed or intended for use with 
4
such a drug or biological product; and 
5
‘‘(B) any product that is— 
6
‘‘(i) a covered part D drug (as defined 
7
in section 1860D–2(e) of the Social Secu-
8
rity Act) eligible for placement on, with re-
9
spect to a plan year, a specialty tier (as de-
10
fined in section 423.560 of title 42, Code 
11
of Federal Regulations) of a formulary for 
12
such plan year of a prescription drug plan 
13
under part D of title XVIII of such Act or 
14
an MA–PD plan under part C of such 
15
title; or 
16
‘‘(ii) a drug (including any biological 
17
product), or combination product, whose 
18
cost is determined by the Commissioner to 
19
be prohibitive to the advancement of quali-
20
fied research. 
21
‘‘(5) ELIGIBLE RESEARCHER.—The term ‘eligi-
22
ble researcher’ means any individual or entity seek-
23
ing to obtain an eligible product for qualified re-
24
search. 
25
00:14 Apr 09, 2022
H7472
11 
•HR 7472 IH
‘‘(6) LICENSE
HOLDER.—The term ‘license 
1
holder’ means the holder of an application approved 
2
under section subsection (c) or (j) of section 505 of 
3
this Act, or a license under subsection (a) or (k) of 
4
section 351 of the Public Health Service Act, for an 
5
eligible product. 
6
‘‘(7) QUALIFIED RESEARCH.—The term ‘quali-
7
fied research’ means— 
8
‘‘(A) research in furtherance of an applica-
9
tion under section 505(b) or (j) of this Act; 
10
‘‘(B) research in furtherance of an applica-
11
tion for a license under section 351(a) or (k) of 
12
the Public Health Service Act; 
13
‘‘(C) research for which an exemption for 
14
investigational use is granted pursuant to sec-
15
tion 505(i) of this Act or section 351(a) of the 
16
Public Health Service Act; or 
17
‘‘(D) research using an approved drug for 
18
an approved indication with the purpose of eval-
19
uating and comparing the clinical effectiveness, 
20
risks, or benefits of 2 or more of any of the fol-
21
lowing: 
22
‘‘(i) Health care interventions, proto-
23
cols for treatment, care management, de-
24
00:14 Apr 09, 2022
H7472
12 
•HR 7472 IH
livery procedures, diagnostic tools, or inte-
1
grative practices. 
2
‘‘(ii) Drugs (including biological prod-
3
ucts), devices, or combination products. 
4
‘‘(iii) Any other treatments, services, 
5
practices, or items being used in the treat-
6
ment, management, or diagnosis of, or pre-
7
vention of, illness or injury in individuals. 
8
‘‘(8) SUFFICIENT QUANTITY.—The term ‘suffi-
9
cient quantity’ means an amount of an eligible prod-
10
uct no greater than the eligible researcher deter-
11
mines to be necessary to accomplish the qualified re-
12
search and fulfill any related regulatory require-
13
ments.’’. 
14
(b) REGULATIONS.—Not later than 180 days of the 
15
date of enactment of this Act, the Secretary of Health and 
16
Human Services shall promulgate final regulations to 
17
carry out section 505–3 of the Federal Food, Drug, and 
18
Cosmetic Act, as added by subsection (a), including regu-
19
lations to appropriately calculate the discounted price ap-
20
plicable with respect to an eligible product (as such terms 
21
are defined in such section 505–3). 
22
Æ 
00:14 Apr 09, 2022
H7472
